机译:先进的糖化末端产品在雌激素受体阳性乳腺癌患者中升高,改变对治疗的反应,可以通过生活方式干预来瞄准
MUSC Dept Pathol &
Lab Med Charleston SC 29425 USA;
MUSC Dept Publ Hlth Sci Charleston SC 29425 USA;
Campbell Univ Coll Arts &
Sci Dept Exercise Sci Buies Creek NC 27506 USA;
MUSC Hollings Canc Ctr Charleston SC 29425 USA;
MUSC Dept Publ Hlth Sci Charleston SC 29425 USA;
MUSC Dept Pathol &
Lab Med Charleston SC 29425 USA;
MUSC Dept Pathol &
Lab Med Charleston SC 29425 USA;
MUSC Dept Pathol &
Lab Med Charleston SC 29425 USA;
MUSC Dept Pathol &
Lab Med Charleston SC 29425 USA;
MUSC Dept Pathol &
Lab Med Charleston SC 29425 USA;
MUSC Dept Pathol &
Lab Med Charleston SC 29425 USA;
NCI Human Carcinogenesis Lab Ctr Canc Res Bldg 37 Bethesda MD 20892 USA;
Frederick Natl Lab Leidos Biomed Res Canc Res Technol Program Frederick MD USA;
MUSC Dietet Serv Charleston SC USA;
MUSC Dept Publ Hlth Sci Charleston SC 29425 USA;
MUSC Dept Publ Hlth Sci Charleston SC 29425 USA;
Icahn Sch Med Mt Sinai Dept Med Renal Med New York NY 10029 USA;
MUSC Dept Publ Hlth Sci Charleston SC 29425 USA;
MUSC Dept Publ Hlth Sci Charleston SC 29425 USA;
MUSC Dept Anesthesia &
Perioperat Med Charleston SC USA;
MUSC Div Cardiol Dept Med Charleston SC USA;
MUSC Div Cardiol Dept Med Charleston SC USA;
MUSC Dept Surg Charleston SC USA;
MUSC Dept Pathol &
Lab Med Charleston SC 29425 USA;
Washington Univ Sch Med St Louis MO USA;
MUSC Coll Nursing Charleston SC USA;
MUSC Dept Pathol &
Lab Med Charleston SC 29425 USA;
Advanced glycation end product; Estrogen receptor; Breast cancer; Tamoxifen resistance; Lifestyle intervention;
机译:先进的糖化末端产品在雌激素受体阳性乳腺癌患者中升高,改变对治疗的反应,可以通过生活方式干预来瞄准
机译:LSZ102的阶段1 / 1B研究,口服选择性雌激素受体降解剂(SERD)与雌激素受体阳性(ER Plus)晚期乳腺癌(ABC)的患者组合,患有内分泌治疗(ET)进行的(ET)
机译:雌激素受体阳性雌激素受体阳性患者患者临床结果和预后因素,用新辅助化疗和手术治疗,后术后辐射治疗
机译:雌激素受体阳性乳腺癌:传统预测,分子病理:新的乳腺癌分类和21世纪个性化预测和预测测定
机译:克服雌激素受体(ER)阳性乳腺癌中的抗雌激素抵抗:磷脂酰肌醇3-激酶(PI3K)的合理靶向和雌激素疗法的复活
机译:晚期糖基化终产物在雌激素受体阳性的乳腺癌患者中升高改变了对治疗的反应并且可以通过生活方式干预来靶向
机译:先进的糖化末端产品在雌激素受体阳性乳腺癌患者中升高,改变对治疗的反应,可以通过生活方式干预来瞄准